Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Instagram Outage Disrupts Thousands of U.S. Users 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
NEWARK, Calif., Feb. 08, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of February.
LEERINK Partners 6th Annual Global Healthcare Conference
Date: Wednesday, February 15, 2017
Time: 3:30 p.m. EST
Location: New York, New York
RBC Capital Markets 2017 Global Healthcare Conference
Date: Thursday, February 23, 2017
Time: 8:00 a.m. EST
Location: New York, New York
The fireside chats will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of these events will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
